13039-79-7

Upstream product

• 43179-48-2 L-arabinose di(ethylthio)acetal 
• 98-59-9 p-toluenesulfonyl chloride 
• 5328-37-0 L-arabinose 

Downstream Products

• 95895-36-6 5-deoxy-2,3,4-O-triacetyl-L-arabinose-phenylhydrazone 
• 59245-36-2 5-deoxy-L-arabinose phenylhydrazone 
• 62933-57-7 1',2'-O-diacetyl-L-biopterin 
• 13391-65-6 N-[(2S,3S,4S)-5-(Benzyl-phenyl-hydrazono)-2,3,4-trihydroxy-pentyl]-acetamide 
• 55955-63-0 5-Acetamino-5-desoxy-L-arabinose-diethyl-dithioacetal 
• 13039-56-0 5-deoxy-L-arabinose 
• 34980-57-9 methyl-[O⁵-(toluene-4-sulfonyl)-α-L-arabinofuranoside] 
• 61329-50-8 O⁵-(toluene-4-sulfonyl)-L-arabinose 
• 6893-65-8 5-O-p-toluenesulfonyl-1,2-O-isopropylidene-L-arabinofuranose 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.